Abstract
The test-trace-isolate-quarantine (TTIQ) strategy is used to break chains of transmission during a disease outbreak. Confirmed-positive pathogen carriers are isolated from the community to prevent onward transmission and their recent close contacts are identified and pre-emptively quarantined. TTIQ, along with mask wearing and social distancing, make up the non-pharmaceutical interventions that are utilised to suppress the ongoing SARS-CoV-2 pandemic. The efficacy of the TTIQ strategy depends on the probability of isolating a case, the fraction of contacts quarantined, and the delays in these processes. Here we use empirical distributions of the timing of SARS-CoV-2 transmission to quantify how these parameters individually contribute to the reduction of onwards infection. We show that finding and isolating index cases, and doing so with minimal delay after symptom onset, have the largest effects on case reduction, and that contact tracing can make up for deficiencies in testing coverage and delays. These results can be used to assess how TTIQ can be improved and optimised. We provide an online application to assess the efficacy as a function of these parameters.
Code is publicly available at http://github.com/ashcroftp.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swiss National Science Foundation. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code is publicly available at http://github.com/ashcroftp.
